Literature DB >> 30716599

Congruence and discrepancy between self-rated and clinician-rated symptom severity on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) before and after a low-intensity intervention.

Marit Hauschildt1, Reuven Dar2, Johanna Schröder3, Steffen Moritz4.   

Abstract

The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is the most common measure of Obsessive-Compulsive symptom severity. The Y-BOCS interview is considered gold standard, but its self-rating format is increasingly used in clinical trials. Few studies investigated congruency and potential changes over treatment. This question is highly relevant, as a systematic bias might obscure results of clinical trials. We examined the relationship of self- and clinician-rated Y-BOCS scores in participants with obsessive-compulsive disorder in pre (N = 128), post, (4 weeks, n = 104) and follow-up (6 months, n = 98) assessments of a randomized-controlled clinical trial. We administered Y-BOCS interview via telephone paralleling online administration of the self-report form. Analyses showed medium-to-strong correlations of Y-BOCS interview and self-rating scores at pre-assessment. Patients rated symptoms lower than clinicians. Larger discrepancies were associated with hoarding and age. Congruency was inferior for obsessions relative to compulsions, largely owing to the "resistance against obsessions" item. Agreement strongly increased at post and follow-up. Though overall congruency between the two Y-BOCS forms was satisfactory, results suggest a "correction over time" effect. Such bias may distort the precise interpretation of treatment effects. Therefore, we made several suggestions to improve the reliability of change scores assessed with the Y-BOCS self-rating.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Assessment; OCD; Obsessive-compulsive disorder; Y-BOCS

Mesh:

Year:  2019        PMID: 30716599     DOI: 10.1016/j.psychres.2019.01.092

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  The Behavior Avoidance Test: Association With Symptom Severity and Treatment Outcome in Obsessive-Compulsive Disorder.

Authors:  Jana Hansmeier; Anke Haberkamp; Julia A Glombiewski; Cornelia Exner
Journal:  Front Psychiatry       Date:  2021-12-21       Impact factor: 5.435

2.  Gender differences in the association of psychological distress and sexual compulsivity before and during the COVID-19 pandemic.

Authors:  Laura I Kürbitz; Christian Wiessner; Wiebke Schoon; Peer Briken; Daniel Schöttle; Johanna Schröder
Journal:  J Behav Addict       Date:  2022-06-30       Impact factor: 7.772

3.  A retrospective research on non-suicidal self-injurious behaviors among young patients diagnosed with mood disorders.

Authors:  Yage Zheng; Ling Xiao; Huiling Wang; Zhenhua Chen; Gaohua Wang
Journal:  Front Psychiatry       Date:  2022-07-22       Impact factor: 5.435

4.  Effects of the COVID-19 Pandemic on Obsessive-Compulsive Symptoms Among University Students: Prospective Cohort Survey Study.

Authors:  Guangjun Ji; Wenjun Wei; Kai-Chen Yue; Heng Li; Li-Jing Shi; Jian-Dong Ma; Chen-Yang He; Sheng-Sheng Zhou; Zongya Zhao; Tao Lou; Jie Cheng; Shi-Chang Yang; Xian-Zhang Hu
Journal:  J Med Internet Res       Date:  2020-09-30       Impact factor: 5.428

5.  Low intensity technology-delivered cognitive behavioral therapy for obsessive-compulsive disorder: a meta-analysis.

Authors:  Laura Marie Hoppen; Nora Kuck; Paul-Christian Bürkner; Eyal Karin; Bethany M Wootton; Ulrike Buhlmann
Journal:  BMC Psychiatry       Date:  2021-06-30       Impact factor: 3.630

6.  Clinical reappraisal of the Composite International Diagnostic Interview Version 3.0 in the Saudi National Mental Health Survey.

Authors:  Ronald C Kessler; Majid Al-Desouki; Andrew J King; Nancy A Sampson; Abdullah S Al-Subaie; Abdulhameed Al-Habeeb; Lisa Bilal; Mona K Shahab; Maggie Aradati; Yasmin A Altwaijri
Journal:  Int J Methods Psychiatr Res       Date:  2020-08-15       Impact factor: 4.182

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.